-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Hangzhou Xianweida Biotechnology Co.
, Ltd.
, a clinical-stage biotechnology company focused on researching and developing innovative treatments for chronic metabolic diseases, announced today that the Phase IIb clinical trial of XW003 for the treatment of obesity has initiated patient dosing
.
XW003 is a novel, long-acting glucagon-like peptide-1 (GLP-1) analog drug independently developed by Xianweida
.
The previously completed Phase I clinical study of XW003 has shown good safety, tolerability and dose-dependent weight loss effect
.
This multicenter, randomized, open-label, active-controlled Phase IIb clinical trial plans to evaluate the efficacy of once-weekly subcutaneous administration of XW003 in approximately 200 obese patients.
The clinical trial is being conducted concurrently in Australia and New Zealand.
Patients will receive 26 weeks of drug treatment and a 5-week follow-up period.
This study aims to evaluate the efficacy of XW003 in obese patients, and further evaluate safety and tolerability.
Top-line data is expected in the second half of 2022 In addition to this international multicenter clinical study, as part of the overall development plan for XW003, a clinical trial in Chinese obese patients is also underway
.
"We are delighted to see that the clinical development of XW003 continues to progress rapidly.
This international multi-center clinical study of XW003 for obesity indications and the initiation of patient dosing is another important milestone in the company's development, and it is also a testament to the pioneering spirit and pioneering spirit of the XW003 team.
A strong proof of our R&D capabilities," said Dr.
Hai Pan, founder and CEO of Xianweida, "We will continue to work on the development of XW003 and other drug candidates in Xianweida's R&D pipeline, including for obesity, diabetes and non-alcoholic fatty diseases.
Innovative therapies for patients with metabolic diseases, including hepatitis (NASH)
.
"
